Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Immunotoxicity and Cytokine Release Syndrome Evaluation for Autologous CAR-T Cell Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Immunotoxicity and Cytokine Release Syndrome Evaluation for Autologous CAR-T Cell Therapies

Immunotoxicity and Cytokine Release Syndrome Evaluation for Autologous CAR-T Therapies

CELL & GENE | RNA | BIOLOGICS

Evaluating the immunotoxic potential of autologous CAR-T cell therapies, specifically Cytokine Release Syndrome (CRS) and neurotoxicity, requires highly specialized preclinical models that can recapitulate human immune responses. A successful Investigational New Drug (IND) submission depends on a robust data package that combines in vitro functional screening, appropriate in vivo humanized models, and a suite of advanced bioanalytical endpoints. Our approach integrates multi-parameter flow cytometry, comprehensive cytokine profiling, and GxP-compliant histology to de-risk clinical development and support an accelerated regulatory timeline.

    What in vivo models are most relevant for CAR-T immunotoxicity?

    A: Humanized preclinical models, such as those engrafted with human peripheral blood mononuclear cells (hu-PBMC) or CD34+ hematopoietic stem cells (hu-CD34+), are the standard for evaluating on-target, off-tumor toxicity and CRS risk.

    How is Cytokine Release Syndrome (CRS) quantified preclinically?

    A: CRS is characterized by analyzing plasma samples from in vivo studies using validated multi-plex cytokine panels. This data is correlated with clinical observations like body weight and temperature to establish a safety profile.

    What is the typical timeline for a full immunotoxicity package?

    A: The timeline for a comprehensive program is scope-dependent. A typical study incorporates in-life monitoring, histology, and flow cytometry endpoints, and we build schedules to align with each sponsor’s specific IND submission goals.

    Can you assess neurotoxicity risk for CAR-T constructs?

    A: Yes. We evaluate the potential for Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) through a combination of functional assessments, cerebrospinal fluid (CSF) analysis, and detailed GxP histology of the central nervous system.

Defining the Preclinical Safety Challenge for CAR-T

The potent mechanism of action that makes CAR-T therapies effective also presents unique safety liabilities. Cytokine Release Syndrome and neurotoxicity are on-target, mechanism-based effects driven by profound immune activation, distinguishing them from classical toxicology events.

Predicting the severity of these events requires preclinical systems that accurately reflect human biology. Standard toxicology models are insufficient. The development of a clinically relevant safety profile hinges on deploying humanized in vivo systems capable of modeling the complex interplay between the engineered T cells, target antigens, and the human immune system.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Integrated In Vitro and In Vivo Evaluation Strategy

A robust immunotoxicity program begins with in vitro characterization. We utilize co-culture systems of CAR-T cells and target-positive tumor cells to quantify baseline cytokine release profiles and cytotoxic activity. This initial screen helps rank-order constructs and identify potential liabilities before committing to resource-intensive in vivo work.

For in vivo evaluation, we execute studies in humanized models within our >100,000 sq ft GxP-compliant facility. A key aspect of this analysis is understanding localized immune responses. Insights from other therapeutic modalities have shown that systemic measurements alone can be insufficient; assessing immune cell activity within the target tissue microenvironment provides a more complete picture of potential safety issues (PMID: 30547050). This principle directly informs our study designs for CAR-T programs.

Key Bioanalytical Endpoints for a Robust IND Package

The data generated from these studies must be suitable for regulatory review. Our programs are designed to produce an IND-ready data package, leveraging our experience to support an 18-24 month IND timeline. This level of detail provides the data-driven safety intelligence engineered for advanced therapeutics that regulatory bodies expect. Since the Franklin Biolabs brand launch in 2024, programs managed by our scientific leadership have maintained a 100% IND success rate since 2019.

Key endpoints include:

  • Multi-plex Cytokine Profiling: Quantitative analysis of key human cytokines (e.g., IL-6, IFN-γ, IL-2) in plasma to model CRS.

  • Multi-parameter Flow Cytometry: Characterization of CAR-T cell persistence, expansion, and phenotype in blood and tissues.

  • GxP Histology: Full tissue collection with expert histological evaluation and immunohistochemistry (IHC) to identify and score tissue damage.

  • Non-target Tissue Biodistribution: Analysis of CAR-T cell localization in relevant tissues using qPCR or ddPCR.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Animal Welfare and Regulatory Compliance

All in vivo studies are conducted in strict compliance with AAALAC and USDA guidelines. Our animal welfare program prioritizes the 3Rs: Reduction, Refinement, and Replacement, ensuring ethical and scientifically sound study execution. This commitment to welfare and GxP standards provides data integrity for global regulatory submissions.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities